Institutional Sign In

Go

Gedeon Richter

Gedeon Richter's Cash & Cash Equivalents rose 35.2% yoy to HUF 132,374 mil in 2015

By Helgi Library - April 2, 2020

Gedeon Richter's total assets reached HUF 749,194 mil at the end of 2015, up 4.05% compared to the previous year. ...

Profit Statement
Balance Sheet
Ratios
Valuation

Get all company financials in excel:

Download Sample   $19.99

Get all company financials in excel:

Download Sample   $19.99

May 2016
Statistical Dossier
Apr 2014
Company Report
Apr 2014
Statistical Dossier

Gedeon Richter Plc. (Richter) is a Hungary-based company specializing in the research, development, production and marketing of pharmaceutical products. The Company focuses in both retail and wholesale market of pharmaceutical products. Its pharmaceutical product range covers therapeutic areas such as cardiovascular, gastrointestinal, gynecology, muscle relaxants, central nervous system and others. Richter has a direct presence in 30 countries with a total of four manufacturing facilities, 14 commercial subsidiaries and wholesalers and 30 representative offices. It sells its pharmaceutical products through its own distribution network to over 100 countries all over the world. Gedeon Richter is headquartered in Budapest, Hungary.

Finance

Gedeon Richter has been growing its sales by a year on average in the last 5 years. EBITDA has grown by 0% during that time to total of in 2015, or of sales. That’s compared to % average margin seen in last five years.

The company netted in 2015 implying ROE of and ROCE of . Again, the average figures were % and %, respectively when looking at the previous 5 years.

Gedeon Richter’s net debt amounted to at the end of 2015, or of equity. When compared to EBITDA, net debt was x, up when compared to average of x seen in the last 5 years.

Valuation

Gedeon Richter stock traded at per share at the end of 2015 resulting in a market capitalization of . Over the previous five years, stock price grew by 0% or % a year on average. The closing price put stock at a 12-month trailing EV/EBITDA of x and price to earnings (PE) of x as of 2015.

More Companies in Hungarian Pharmaceutical Sector